LncRNA HOXA11-AS drives cisplatin resistance of human LUAD cells via modulating miR-454-3p/Stat3.

Zhao, Xia; Li, Xiaoyou; Zhou, Leilei; Ni, Jie; Yan, Wenyue; Ma, Rong; Wu, Jianzhong; Feng, Jifeng; Chen, Ping

Zhao, Xia; Li, Xiaoyou; Zhou, Leilei; Ni, Jie; Yan, Wenyue; Ma, Rong; Wu, Jianzhong; Feng, Jifeng; Chen, Ping.

Afiliación

Zhao X; Department of Oncology, First People's Hospital of Yancheng, Fourth Affiliated Hospital of Nantong University, Yancheng, China.
Li X; Department of Medical Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
Zhou L; Department of Oncology, The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, Huai'an, China.
Ni J; Department of Medical Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
Yan W; Department of Oncology, First People's Hospital of Yancheng, Fourth Affiliated Hospital of Nantong University, Yancheng, China.
Ma R; Department of Medical Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
Wu J; Department of Medical Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
Feng J; Department of Medical Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
Chen P; Department of Oncology, First People's Hospital of Yancheng, Fourth Affiliated Hospital of Nantong University, Yancheng, China.

Cancer Sci ; 109(10): 3068-3079, 2018 Oct.

Article en En | MEDLINE | ID: mdl-30099826

Asunto(s)

Adenocarcinoma/tratamiento farmacológico; Antineoplásicos/farmacología; Resistencia a Antineoplásicos/genética; Regulación Neoplásica de la Expresión Génica; Neoplasias Pulmonares/tratamiento farmacológico; ARN Largo no Codificante/metabolismo; Adenocarcinoma/genética; Adenocarcinoma/patología; Adenocarcinoma del Pulmón; Antineoplásicos/uso terapéutico; Línea Celular Tumoral; Cisplatino/farmacología; Cisplatino/uso terapéutico; Transición Epitelial-Mesenquimal/genética; Técnicas de Silenciamiento del Gen; Células HEK293; Humanos; Neoplasias Pulmonares/genética; Neoplasias Pulmonares/patología; MicroARNs/genética; MicroARNs/metabolismo; ARN Largo no Codificante/genética; Factor de Transcripción STAT3/genética; Factor de Transcripción STAT3/metabolismo; Transducción de Señal/efectos de los fármacos; Transducción de Señal/genética

Palabras clave

Cisplatin resistance; HOXA11-AS; Stat3; lung adenocarcinoma; miR-454-3p

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Adenocarcinoma / Regulación Neoplásica de la Expresión Génica / Resistencia a Antineoplásicos / ARN Largo no Codificante / Neoplasias Pulmonares / Antineoplásicos Límite: Humans Idioma: En Revista: Cancer Sci Año: 2018 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google